thrombolytic agent + heparin

This entry refers to a **combination therapy** of a *thrombolytic agent* and *heparin*, typically used in acute management of thromboembolic diseases, such as acute myocardial infarction, pulmonary embolism, deep vein thrombosis, and acute ischemic stroke. - **Thrombolytic agents** (sometimes called fibrinolytics) are a class of drugs including recombinant tissue plasminogen activators like alteplase, tenecteplase, reteplase, as well as urokinase, streptokinase, and anistreplase. These drugs work by directly or indirectly converting plasminogen into plasmin, an enzyme that degrades fibrin clots, thereby dissolving thrombi[2][3]. - **Heparin** is an *anticoagulant* (blood thinner) that potentiates the action of antithrombin III, inhibiting thrombin and factor Xa, thus preventing the formation and propagation of clots; it does not directly dissolve established clots. - Combined therapy is sometimes used when aggressive lysis of established clot is needed alongside prevention of new thrombus formation. There are specific clinical scenarios (e.g., pulmonary embolism, severe deep vein thrombosis, acute coronary syndromes) where both drugs may be used sequentially or in overlapping fashion; however, the combination can increase bleeding risk, so is reserved for selected, monitored, and guideline-driven settings[2].